Vaccination Strategy for Varicella‑Naïve Adults Initiating Tofacitinib

1. Pre‑Therapy Assessment

Verify absence of prior varicella infection or vaccination and obtain VZV IgG serology when history is uncertain (e.g., patients from tropical regions).  1

Administer a two‑dose series of the live varicella vaccine (Varivax), spaced 4 weeks apart, and postpone initiation of tofacitinib until at least 4 weeks after the second dose.  1
The UK Department of Health advises a minimum 4‑week interval between any live vaccine and the commencement of immunosuppressive therapy to allow adequate immune response.  1

Live varicella vaccination must be completed prior to any JAK‑inhibitor therapy; live vaccines are absolutely contraindicated once tofacitinib is started.  1
The FDA label for tofacitinib reports a case of disseminated vaccine‑strain VZV occurring shortly after a live zoster vaccine (Zostavax) was given to a varicella‑naïve patient who had just begun tofacitinib, underscoring the prohibition of live vaccines after therapy initiation.  1

After successful varicella vaccination and confirmed VZV seropositivity, a recombinant zoster vaccine (Shingrix) may be administered only later—typically at age ≥ 50 years, or at age ≥ 18 years if the patient remains on a JAK inhibitor.  [1][2]
Shingrix is designed to boost cell‑mediated immunity against reactivation of latent VZV and does not protect against primary varicella infection; therefore it is not indicated before establishing VZV immunity.  2

If disease severity precludes the 8‑week vaccination window, do not give a live varicella vaccine after tofacitinib has started.  1
Counsel the patient to avoid exposure to individuals with active chickenpox or shingles and to seek post‑exposure prophylaxis (e.g., oral acyclovir for 7 days, beginning 7 days after exposure) if contact occurs.  1

Step‑wise plan:
Withhold any other immunomodulatory agents for 4 weeks after each live vaccine dose to ensure optimal seroconversion.  1

Do not confuse varicella (chickenpox) vaccination with herpes zoster (shingles) vaccination; they address distinct clinical scenarios.  2
Do not assume that lack of recalled chickenpox history equates to seronegativity—although 88–91 % of adults have prior VZV exposure, a documented absence of infection and vaccination warrants serologic testing or presumptive varicella vaccination.  2
Do not use the live zoster vaccine (Zostavax) in patients about to start or already receiving tofacitinib; the recombinant Shingrix vaccine is the appropriate zoster preventive measure only after VZV immunity is established.  [1][3]4
Avoid simultaneous or sequential administration of Varivax and Shingrix before tofacitinib initiation, as Shingrix provides no benefit for primary varicella protection and may cause unnecessary adverse effects.  [1][2]